NEW YORK (360Dx) – Myriad Genetics' subsidiary Crescendo Bioscience presented data last week at the European League Against Rheumatism (EULAR) annual meeting in Madrid that indicates the company's Vectra DA rheumatoid arthritis test can help identify patients at risk of radiographic progression.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.